Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative Study of Weekly GLP-1 RAs in Diabetic and Non-Diabetic Obese Patients
NCT07820111Phase 3Completed
- Sponsor
- Zagazig University
- Start
- Oct 2025
- Primary completion
- Mar 2026
- Countries
- 1
01
Overview
Phase 3, randomised trial of dulaglutide biosimilar 14028 injection, semaglutide and tirzepatide in obesity and type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Zagazig University. Primary endpoint: Change in body weight at 6 months. Started Oct 2025; status: completed.
02
Drugs
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07820111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07820111.